COPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ — Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targetedCOPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ — Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted

Curasight to present at TD Cowen’s 46th Annual Health Care Conference in Boston

2026/02/17 15:15
2 min read

COPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ — Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies across multiple aggressive solid tumors, will present recent company progress including the ongoing Phase 1 clinical trial uTREAT® in glioblastoma, at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd, 2026, at 11:50 a.m. Eastern Time / 5:50 p.m. CET in Boston. 

A live audio webcast will be broadcast over the internet simultaneously and will be available in the investor section on Curasight.com approximately 48 hours after the webcast.

During the conference, Curasight management will also hold 1:1 meetings with investors and other industry stakeholders.

The TD Cowen conference is a major investor conference where public and private healthcare companies meet with institutional investors, and large pharma via scheduled 1×1 meetings and presentations combined with fireside chats and innovative panel discussions.

About Curasight A/S

Curasight is advancing uTREAT®, a clinical-stage, first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat solid tumors. uTREAT® targets uPAR, a key driver of tumor invasion, angiogenesis, and metastasis, which is expressed in more than 85% of solid tumors.

The company’s theranostic platform also includes uTRACE®, a uPAR-PET imaging agent built on the same proprietary ligand as uTREAT®. uTRACE® supports patient selection and confirms tumor targeting and has been evaluated in more than 450 patients across nine Phase II trials in eight solid tumor indications.

The uPAR platform is based on more than a decade of research at the Copenhagen University Hospital and the University of Copenhagen.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
E-mail: uk@curasight.com
www.curasight.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/curasight/r/curasight-to-present-at-td-cowen-s-46th-annual-health-care-conference-in-boston,c4308454

The following files are available for download:

https://mb.cision.com/Main/19744/4308454/3937544.pdf

260217 Curasight Press release – TDCowen

Cision View original content:https://www.prnewswire.com/news-releases/curasight-to-present-at-td-cowens-46th-annual-health-care-conference-in-boston-302689307.html

SOURCE Curasight

Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.0006643
$0.0006643$0.0006643
-2.45%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

The Channel Factories We’ve Been Waiting For

The Channel Factories We’ve Been Waiting For

The post The Channel Factories We’ve Been Waiting For appeared on BitcoinEthereumNews.com. Visions of future technology are often prescient about the broad strokes while flubbing the details. The tablets in “2001: A Space Odyssey” do indeed look like iPads, but you never see the astronauts paying for subscriptions or wasting hours on Candy Crush.  Channel factories are one vision that arose early in the history of the Lightning Network to address some challenges that Lightning has faced from the beginning. Despite having grown to become Bitcoin’s most successful layer-2 scaling solution, with instant and low-fee payments, Lightning’s scale is limited by its reliance on payment channels. Although Lightning shifts most transactions off-chain, each payment channel still requires an on-chain transaction to open and (usually) another to close. As adoption grows, pressure on the blockchain grows with it. The need for a more scalable approach to managing channels is clear. Channel factories were supposed to meet this need, but where are they? In 2025, subnetworks are emerging that revive the impetus of channel factories with some new details that vastly increase their potential. They are natively interoperable with Lightning and achieve greater scale by allowing a group of participants to open a shared multisig UTXO and create multiple bilateral channels, which reduces the number of on-chain transactions and improves capital efficiency. Achieving greater scale by reducing complexity, Ark and Spark perform the same function as traditional channel factories with new designs and additional capabilities based on shared UTXOs.  Channel Factories 101 Channel factories have been around since the inception of Lightning. A factory is a multiparty contract where multiple users (not just two, as in a Dryja-Poon channel) cooperatively lock funds in a single multisig UTXO. They can open, close and update channels off-chain without updating the blockchain for each operation. Only when participants leave or the factory dissolves is an on-chain transaction…
Share
BitcoinEthereumNews2025/09/18 00:09
Bitcoin, Ethereum, XRP, Dogecoin Surge With Stocks, But Analyst Warns This Might Just Be A 'Relief Rally'

Bitcoin, Ethereum, XRP, Dogecoin Surge With Stocks, But Analyst Warns This Might Just Be A 'Relief Rally'

Leading cryptocurrencies jumped on Wednesday, though analysts view the uptick as a relief bounce rather than a momentum shift.read more
Share
Coinstats2026/02/26 10:04
The Chen Zhi case and the Zhao Changpeng case: The United States profited nearly $20 billion from them.

The Chen Zhi case and the Zhao Changpeng case: The United States profited nearly $20 billion from them.

Author: Yuan Hong , Global Times On February 26, a new report jointly released by the National Computer Virus Emergency Response Center of China and other departments
Share
PANews2026/02/26 11:18